BX430

BX430 is an antagonist of P2 Receptors used in studies of Immune Signaling and GPCR Signaling. In practice, this places the compound in experiments that measure cytokine-mediated signaling and inflammatory effector responses and receptor-driven second-messenger signaling and desensitization dynamics in cardiovascular, inflammation, and neuroscience models.

By blocking P2 Receptors, BX430 can be used to examine cytokine-mediated signaling and inflammatory effector responses and receptor-driven second-messenger signaling and desensitization dynamics. The gpcr annotation adds relevance to GPCR pharmacology, ligand-binding, and signaling assays, together with downstream-response mapping in the same experimental setting. In cardiovascular, inflammation, and neuroscience models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving P2 Receptors
• Pathway perturbation studies connected to Immune Signaling and GPCR Signaling
• Receptor-blockade and ligand-competition studies
• GPCR pharmacology, ligand-binding, and signaling assays

Overall, BX430 is appropriate when a defined chemical perturbant is needed to connect P2 Receptors with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cardiovascular, inflammation, and neuroscience models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.